36 patents
Utility
Transient Protection of Normal Cells During Chemotherapy
30 Nov 23
This invention is in the area of improved compounds, compositions and methods of transiently protecting healthy cells, and in particular hematopoietic stem and progenitor cells (HSPC) as well as renal cells, from damage associated with DNA damaging chemotherapeutic agents.
Jay Copeland Strum, John Emerson Bisi, Patrick Joseph Roberts, Francis Xavier Tavares
Filed: 7 Aug 23
Utility
Hspc-sparing Treatments for Rb-positive Abnormal Cellular Proliferation
16 Nov 23
This invention is in the area of improved compounds for and methods of treating selected RB-positive cancers and other Rb-positive abnormal cellular proliferative disorders while minimizing the deleterious effects on healthy cells, for example healthy Hematopoietic Stem Cells and Progenitor Cells (HSPCs), associated with current treatment modalities.
Jay Copeland Strum, John Emerson Bisi, Patrick Joseph Roberts, Francis X. Tavares
Filed: 6 Mar 23
Utility
Preservation of Immune Response During Chemotherapy Regimens
28 Sep 23
The addition of a selective, fast-acting, short half-life CDK 4/6 inhibitor in a very specific dosage regimen to the combination of chemotherapy with a checkpoint inhibitor provides superior results in the treatment of a tumor or cancer.
Jessica A. Sorrentino, Anne Y. Lai, Jay C. Strum, Patrick Joseph Roberts
Filed: 1 Dec 22
Utility
Highly Active Anti-neoplastic and Anti-proliferative Agents
10 Aug 23
This invention is in the area of improved compounds and methods for treating selected cancers and hyperproliferative disorders.
Jay Copeland Strum, John Emerson Bisi, Patrick Joseph Roberts, Francis Xavier Tavares
Filed: 17 Aug 22
Utility
Anti-neoplastic Combinations and Dosing Regimens Using CDK4/6 Inhibitor Compounds to Treat Rb-positive Tumors
3 Aug 23
This invention directed to methods for treating select RB-positive cancers and other Rb-positive abnormal cellular proliferative disorders using CDK4/6 inhibitors in specific dosing and combination or alternation regimes.
Jay Copeland Strum, John E. Bisi, Patrick Joseph Roberts, Jessica A. Sorrentino, Hannah S. White
Filed: 29 Aug 22
Utility
G1T38 Superior Dosage Regimes
18 May 23
A G1T38 human oral dosage regime that provides a (mean AUC(0-24),ss (h*ng/mL))/(dose (mg)) ratio of less than 5 and/or a (mean AUC(0-24),ss (h*ng/mL))/(Absolute Neutrophil Count (cells/mm3)) ratio on day 22 of dosing of not greater than 1.25.
Andrew Beelen, Jay Copeland Strum
Filed: 13 Jun 22
Utility
Treatment of EGFR-Driven Cancer with Fewer Side Effects
11 May 23
The present invention provides methods for treating a EGFR-mutant cancer in a patient by administering a selective CDK4/6 inhibitor described herein in combination or alternation with an EGFR-TKI to delay or reverse acquired resistance to previously administered EGFR-TKIs.
Jessica A. Sorrentino, Jay Copeland Strum, John E. Bisi, Andrew Beelen
Filed: 30 Jun 22
Utility
Morphic Forms of G1T38 and Methods of Manufacture Thereof
9 Feb 23
Alexander Smith, Hannah S. White, Patricia Andres, Xufeng Sun, Lei Zhu, Petinka I. Vlahova
Filed: 28 Feb 22
Utility
Cyclin-dependent Kinase Inhibiting Compounds for the Treatment of Medical Disorders
29 Sep 22
This invention is in the area of cell cycle inhibiting compounds for the treatment of disorders involving abnormal cellular proliferation, and include selective CDK2 inhibitors for medical therapy and their pharmaceutically acceptable salts and compositions.
Jay Copeland Strum
Filed: 11 May 22
Utility
Targeted Treatment of Cancers with Dysregulated Fibroblast Growth Factor Receptor Signaling
4 Aug 22
The present invention provides advantageous methods and compositions for treating a host having a cancer with dysregulation of the FGFR signaling pathway, which includes administering an effective amount of a selective CDK4/6 inhibitor described herein in combination or alternation with a fibroblast growth factor receptor inhibitor.
Jay Copeland Strum, Chloe Whitworth, Daniel M. Freed
Filed: 11 Apr 22
Utility
Patient Selection for Enhancement of Anti-tumor Immunity In Cancer Patients
9 Jun 22
A method for increasing the progression free survival or overall survival of a patient with cancer comprising: determining if the cancer has a surrounding microenvironment that is favorable to immune modulation; determining if the chemotherapy regimen induces immunogenic cell death, and if both are yes, administering an effective amount of a CDK 4/6 inhibitor selected from Compounds I, II, III, IV, or V, or a pharmaceutically acceptable salt thereof, wherein the CDK4/6 inhibitor is administered prior to the administration of the chemotherapy or optionally prior to and concurrently with chemotherapy; and, wherein the increase in progression free survival or overall survival is in comparison to the progression free survival or overall survival based on administration of the chemotherapy alone, either based on literature or otherwise publicly available evidence, a comparative during preclinical or clinical trials, or other means accepted by persons skilled in the field.
Patrick Joseph Roberts, Anne Lai, Jessica Sorrentino
Filed: 17 Dec 21
Utility
Treatment of Rb-negative Tumors Using Topoisomerase Inhibitors In Combination with Cyclin Dependent Kinase 4/6 Inhibitors
9 Jun 22
This invention is in the area of improved therapeutic combinations for and methods of treating selected retinoblastoma (Rb)-negative cancers and Rb-negative abnormal cellular proliferative disorders using particular topoisomerase inhibitors and specific cyclin-dependent kinase 4/6 (CDK4/6) inhibitors.
Jay Copeland Strum, John E. Bisi, Patrick Joseph Roberts, Jessica A. Sorrentino
Filed: 16 Aug 21
Utility
CDK Inhibitors
23 Dec 21
Compounds of Formulae I, II or III, and pharmaceutically acceptable salts thereof, are useful as CDK inhibitors.
Francis X. Tavares, Jay Copeland Strum
Filed: 20 Jan 21
Utility
Morphic Forms of Trilaciclib and Methods of Manufacture Thereof
16 Dec 21
An advantageous isolated morphic form of trilaciclib which is 2′-((5-(4-methylpiperazin-1-yl)pyridin-2-yl)amino)-7′,8′-dihydro-6′H-spiro[cyclohexane-1,9′-pyrazino[1′,2′:1, 5]pyrrolo[2,3 -d]pyrimidin]-6′-one, for example in the form of a di-hydrochloride salt or a dihydrochloride, dihydrate.
Stephen Schneider, Alexander Smith, Hannah S. White, Jay Copeland Strum, Jaroslaw Mazurek
Filed: 21 Apr 21
Utility
Transient Protection of Normal Cells During Chemotherapy
30 Sep 21
This invention is in the area of improved compounds, compositions and methods of transiently protecting healthy cells, and in particular hematopoietic stem and progenitor cells (HSPC) as well as renal cells, from damage associated with DNA damaging chemotherapeutic agents.
Jay Copeland Strum, John Emerson Bisi, Patrick Joseph Roberts, Francis Xavier Tavares
Filed: 5 Apr 21
Utility
Therapeutic Regimens for Treatment of Cancer Using Eribulin and Selective CDK4/6 Inhibitor Combinations
2 Sep 21
The present invention provides methods and compositions for treating cancers with a combination of eribulin and a selective CDK4/6 inhibitor, wherein the selective CDK4/6 inhibitor reduces eribulin's effects on myelosuppression and/or myeloablation without reducing the efficacy of eribulin therapy.
Jessica A. Sorrentino, Patrick Joseph Roberts, Jay Copeland Strum
Filed: 7 May 21
Utility
Hspc-sparing Treatments for Rb-positive Abnormal Cellular Proliferation
15 Jul 21
This invention is in the area of improved compounds for and methods of treating selected RB-positive cancers and other Rb-positive abnormal cellular proliferative disorders while minimizing the deleterious effects on healthy cells, for example healthy Hematopoietic Stem Cells and Progenitor Cells (HSPCs), associated with current treatment modalities.
Jay Copeland Strum, John Emerson Bisi, Patrick Joseph Roberts, Francis X. Tavares
Filed: 22 Feb 21
Utility
Synthesis of 1,4-DIAZASPIRO[5.5]UNDECAN-3-ONE
17 Jun 21
This invention provides a process for preparing 1,4-diazaspiro[5.5]undecan-3-one and analogues thereof that are useful in the preparation of pharmaceutical compound, including for the treatment of disorders involving abnormal cellular proliferation.
Stephen E. Schneider, Hannah White, Thomas Fessard, Sagar Beldar
Filed: 24 Feb 21
Utility
Benzothiophene Estrogen Receptor Modulators to Treat Medical Disorders
10 Jun 21
This invention is a benzothiophene estrogen receptor modulator or its pharmaceutically acceptable salt, N-oxide, isotopic derivative, or prodrug thereof or a pharmaceutically acceptable composition thereof to treat an estrogen-related medical disorder.
Jay Copeland Strum
Filed: 16 Feb 21
Utility
Synthesis of N-(HETEROARYL)-PYRROLO[3,2-D]PYRIMIDIN-2-AMINES
29 Apr 21
This invention is in the area of synthesizing pyrimidine-based compounds useful in the treatment of disorders involving abnormal cellular proliferation, including but not limited to tumors and cancers.
Alexander Smith, Hannah S. White, Francis Xavier Tavares, Sergiy Krasutsky, Jian-Xie Chen, Roberta L. Dorrow, Hua Zhong
Filed: 14 Dec 20